Long Agonist Protocol — Pituitary Suppression IVF

The long GnRH agonist protocol uses pre-stimulation pituitary downregulation for tight cycle control. Best evidence base for endometriosis and adenomyosis. This page explains the protocol, when it is preferred over antagonist, and what to expect across the 3–5 week cycle.

1. How the long agonist protocol works

GnRH agonist (Lupride, Buserelin, Triptorelin) started in mid-luteal phase of the preceding cycle (cycle day 21). Initial flare of FSH/LH followed by progressive pituitary downregulation over 2–3 weeks. After confirmed suppression (low estradiol, no follicles above 10 mm), FSH stimulation begins. Trigger when follicles 17–18 mm; agonist continued until trigger.

2. Why downregulation matters

Full pituitary suppression prevents any LH surge during stimulation — no premature ovulation. Synchronises follicle cohort recruitment for more uniform development. Provides predictable, controllable cycle. Suppresses any cyclical disease activity (endometriosis, adenomyosis) during the stimulation period. Particularly valuable when timing matters or disease activity threatens implantation.

3. Who benefits most

Endometriosis — particularly stage III–IV with active inflammation. Adenomyosis — suppression during stimulation and transfer may improve implantation. Normal good responders without OHSS concerns. Patients requiring tight cycle control for scheduling. Some studies suggest improved per-cycle pregnancy rates in selected groups (debated by modern meta-analyses).

4. Day-by-day timeline

Cycle preceding stimulation, day 21: start agonist. Day 28 of that cycle (or first day of next period): baseline assessment. Continue agonist 1–2 weeks. After confirmed suppression: start FSH. Stimulation 10–12 days. Trigger. Retrieval. Total time from agonist start to retrieval: 3–5 weeks.

5. Limitations and considerations

Longer cycle than antagonist. Higher OHSS risk than antagonist (especially in PCOS — antagonist preferred there). Initial flare effect with agonist may temporarily increase estrogen and discomfort. Hot flushes from oestrogen suppression during downregulation phase. Higher psychological burden of longer cycle. Higher cumulative medication exposure.

6. Ultra-long variant

For severe endometriosis or adenomyosis — agonist for 2–3 months before stimulation begins. Achieves deep disease suppression. Improved implantation rates in some endometriosis studies. Long duration limits utility for time-critical patients. Add-back oestrogen sometimes used to mitigate menopausal side effects.

7. Side effects during downregulation

Hot flushes, mood changes, headaches, vaginal dryness — typical menopausal symptoms during 2–3 week downregulation phase. Resolve once FSH stimulation begins. Some patients tolerate poorly; antagonist or ultra-short protocol preferred in those cases.

8. Decision: long agonist or antagonist?

Antagonist is now first-line for most patients per international consensus. Long agonist preferred in: stage III–IV endometriosis, significant adenomyosis, selected good responders preferring tight cycle control, specific scheduling needs. Final decision individualised at consultation.

Frequently Asked Questions

Dr. Priyadatt Patel

Senior Gynecologist · Advanced Laparoscopic Surgeon · IVF and Endometriosis Programme Lead

MS OBGyn · Pregnancy Care · Advanced Gynaecological Ultrasound · Fertility Preservation

ESHRE / ESGE / AAGL / ASRM guideline-aligned practice. 3D Karl Storz precision technique. Fertility-preservation-first philosophy. Evidence-based decisions, honest counselling, long-term outcomes orientation.